Remove 2022 Remove Competition Remove Pharmaceutical manufacturing
article thumbnail

Elevating pharmaceutical manufacturing processes with real-time insights

European Pharmaceutical Review

These insights help to drive highly efficient manufacturing processes, ensuring competitive product delivery on time and within budget. However, historically, NMR instruments have rarely been deployed during the later stages of pilot testing and manufacturing operations, even when driven by PAT setups.

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

FDI experts at Investment Monitor have highlighted the following list of factors as most important to life sciences companies considering a greenfield investment in 2022: labour, education, industry clusters, domestic market, infrastructure, business environment, costs and quality of life. appeared first on Pharmaceutical Technology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing. ” Image from the Association of the British Pharmaceutical Industry (ABPI).

article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. However, as we near the end of the year, there were some big moves.

Pharma 109
article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%. Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. Looking back at 2023 , AI for drug discovery saw both wins and losses.

Pharma 95
article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Green Chemistry in the Synthesis of Pharmaceuticals.